370 related articles for article (PubMed ID: 32431217)
1. Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (M
Kumar V; Dhanjal JK; Kaul SC; Wadhwa R; Sundar D
J Biomol Struct Dyn; 2021 Jul; 39(11):3842-3854. PubMed ID: 32431217
[TBL] [Abstract][Full Text] [Related]
2. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.
Kumar V; Dhanjal JK; Bhargava P; Kaul A; Wang J; Zhang H; Kaul SC; Wadhwa R; Sundar D
J Biomol Struct Dyn; 2022 Jan; 40(1):1-13. PubMed ID: 32469279
[TBL] [Abstract][Full Text] [Related]
3. Anti-COVID-19 Potential of Withaferin-A and Caffeic Acid Phenethyl Ester.
Kumar V; Sari AN; Gupta D; Ishida Y; Terao K; Kaul SC; Vrati S; Sundar D; Wadhwa R
Curr Top Med Chem; 2024; 24(9):830-842. PubMed ID: 38279743
[TBL] [Abstract][Full Text] [Related]
4. Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers.
Malik V; Kumar V; Kaul SC; Wadhwa R; Sundar D
Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33530424
[TBL] [Abstract][Full Text] [Related]
5. Effect of Withaferin-A, Withanone, and Caffeic Acid Phenethyl Ester on DNA Methyltransferases: Potential in Epigenetic Cancer Therapy.
Kumar V; Dhanjal JK; Sari AN; Khurana M; Kaul SC; Wadhwa R; Sundar D
Curr Top Med Chem; 2024; 24(4):379-391. PubMed ID: 37496252
[TBL] [Abstract][Full Text] [Related]
6. Identification of bioactive molecule from
Tripathi MK; Singh P; Sharma S; Singh TP; Ethayathulla AS; Kaur P
J Biomol Struct Dyn; 2021 Sep; 39(15):5668-5681. PubMed ID: 32643552
[TBL] [Abstract][Full Text] [Related]
7.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
8. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
Ancy I; Sivanandam M; Kumaradhas P
J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
[TBL] [Abstract][Full Text] [Related]
9. Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target.
Kundu D; Selvaraj C; Singh SK; Dubey VK
J Biomol Struct Dyn; 2021 Jun; 39(9):3428-3434. PubMed ID: 32362243
[TBL] [Abstract][Full Text] [Related]
10. Potential of NO donor furoxan as SARS-CoV-2 main protease (M
Al-Sehemi AG; Pannipara M; Parulekar RS; Patil O; Choudhari PB; Bhatia MS; Zubaidha PK; Tamboli Y
J Biomol Struct Dyn; 2021 Sep; 39(15):5804-5818. PubMed ID: 32643550
[TBL] [Abstract][Full Text] [Related]
11. Finding potent inhibitors for COVID-19 main protease (M
Motiwale M; Yadav NS; Kumar S; Kushwaha T; Choudhir G; Sharma S; Singour PK
J Biomol Struct Dyn; 2022 Mar; 40(4):1534-1545. PubMed ID: 33030102
[TBL] [Abstract][Full Text] [Related]
12. Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19.
Rehman MT; AlAjmi MF; Hussain A
Curr Pharm Des; 2021; 27(33):3577-3589. PubMed ID: 33200697
[TBL] [Abstract][Full Text] [Related]
13. In-silico drug repurposing for targeting SARS-CoV-2 main protease (M
Sharma S; Deep S
J Biomol Struct Dyn; 2022 Apr; 40(7):3003-3010. PubMed ID: 33179568
[TBL] [Abstract][Full Text] [Related]
14. Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease.
Kumar N; Sood D; van der Spek PJ; Sharma HS; Chandra R
J Proteome Res; 2020 Nov; 19(11):4678-4689. PubMed ID: 32786685
[TBL] [Abstract][Full Text] [Related]
15. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
16. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study.
Das S; Sarmah S; Lyndem S; Singha Roy A
J Biomol Struct Dyn; 2021 Jun; 39(9):3347-3357. PubMed ID: 32362245
[TBL] [Abstract][Full Text] [Related]
17. Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings.
Avti P; Chauhan A; Shekhar N; Prajapat M; Sarma P; Kaur H; Bhattacharyya A; Kumar S; Prakash A; Sharma S; Medhi B
J Biomol Struct Dyn; 2022; 40(19):8894-8904. PubMed ID: 33998950
[TBL] [Abstract][Full Text] [Related]
18. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors.
Ibrahim MAA; Abdelrahman AHM; Hussien TA; Badr EAA; Mohamed TA; El-Seedi HR; Pare PW; Efferth T; Hegazy MF
Comput Biol Med; 2020 Nov; 126():104046. PubMed ID: 33065388
[TBL] [Abstract][Full Text] [Related]
19. Computational discovery of small drug-like compounds as potential inhibitors of SARS-CoV-2 main protease.
Andrianov AM; Kornoushenko YV; Karpenko AD; Bosko IP; Tuzikov AV
J Biomol Struct Dyn; 2021 Sep; 39(15):5779-5791. PubMed ID: 32662333
[TBL] [Abstract][Full Text] [Related]
20. Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation.
Kumar D; Kumari K; Vishvakarma VK; Jayaraj A; Kumar D; Ramappa VK; Patel R; Kumar V; Dass SK; Chandra R; Singh P
J Biomol Struct Dyn; 2021 Aug; 39(13):4671-4685. PubMed ID: 32567995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]